Last reviewed 2026-04-20 · How we verify

R. P. 2259 (GLYBUTHIAZOL)

Phase 2 active Small molecule

R. P. 2259 (generic name: GLYBUTHIAZOL) is a glybuthiazol drug. It is currently in Phase 2 development.

Glybuthiazol is thought to work by interacting with a specific molecular target, although this target is currently unknown.

R. P. 2259, also known as Glybuthiazol, is a small molecule drug in the glybuthiazol class. Unfortunately, there is limited information available on this compound, including its target, approved indications, and commercial status. As a result, it is difficult to provide a comprehensive summary of its use and safety profile. Further research is needed to determine the potential benefits and risks of Glybuthiazol. Currently, there is no information available on its half-life, bioavailability, or generic manufacturers.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLYBUTHIAZOL
Drug class	glybuthiazol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Glybuthiazol is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This interaction can help regulate various bodily functions, but more research is needed to understand exactly how Glybuthiazol works.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

R. P. 2259 CI brief — competitive landscape report
R. P. 2259 updates RSS · CI watch RSS

Frequently asked questions about R. P. 2259

What is R. P. 2259?

R. P. 2259 (GLYBUTHIAZOL) is a glybuthiazol drug.

How does R. P. 2259 work?

Glybuthiazol is thought to work by interacting with a specific molecular target, although this target is currently unknown.

What is the generic name of R. P. 2259?

GLYBUTHIAZOL is the generic (nonproprietary) name of R. P. 2259.

What drug class is R. P. 2259 in?

R. P. 2259 belongs to the glybuthiazol class. See all glybuthiazol drugs at /class/glybuthiazol.

What development phase is R. P. 2259 in?

R. P. 2259 is in Phase 2.

Drug class: All glybuthiazol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing